Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

The H3K27M mutation in diffuse midline gliomas increases CD99 expression, which is associated with poor prognosis.

• CD99 is notably expressed in diffuse midline gliomas, especially in those with the K27M mutation.
• Inactivation of CD99 in K27M+ glioma cells impairs tumor growth by promoting cell differentiation.
• The anti-CD99 chimeric antibody, 10D1, demonstrates antitumor efficacy by inducing apoptosis in both laboratory and animal models.
• Combining 10D1 with radiation therapy enhances its effectiveness and extends survival in xenograft models.
• These findings support the clinical development of 10D1 as a potential therapy for treating K27M+ diffuse midline gliomas.

AI simplified